A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2023-01-17
Adverse events
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-02-01 (study day 8); relationship: not assessed
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-03-03 (study day 38); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-22 (study day 57); relationship: N
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-04-02 (study day 68); relationship: not assessed
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-04-19 (study day 85); relationship: not assessed
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-06-13 (study day 140); relationship: not assessed
Data queries
No data queries.